Published in Ann Rheum Dis on November 29, 2007
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum (2011) 2.14
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis (2011) 2.13
Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol (2009) 1.95
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum (2013) 1.80
Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol (2011) 1.77
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ (2009) 1.76
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One (2012) 1.63
A genome-wide association study of myasthenia gravis. JAMA Neurol (2015) 1.52
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis (2013) 1.45
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis (2011) 1.42
Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. PLoS One (2015) 1.40
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis (2017) 1.39
Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther (2011) 1.35
Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther (2011) 1.29
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective. Curr Rheumatol Rev (2011) 1.23
Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res Ther (2008) 1.14
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis (2008) 1.12
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis (2016) 1.11
Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) (2010) 1.10
Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). Ann Rheum Dis (2011) 1.08
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther (2011) 1.05
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis (2012) 1.04
Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) (2010) 1.03
My treatment approach to rheumatoid arthritis. Mayo Clin Proc (2012) 1.02
Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nat Rev Rheumatol (2013) 1.01
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther (2010) 0.97
Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev (2009) 0.96
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther (2016) 0.95
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther (2016) 0.93
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ (2014) 0.92
Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther (2008) 0.91
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis (2013) 0.91
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clin Rheumatol (2013) 0.90
Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol (2014) 0.89
Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology (Oxford) (2014) 0.89
Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Health Qual Life Outcomes (2014) 0.88
Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol (2014) 0.88
Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics (2009) 0.86
Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis. BMC Bioinformatics (2013) 0.86
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis (2011) 0.86
Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med (2010) 0.84
Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol (2016) 0.84
Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol (2013) 0.84
Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals. Rheumatology (Oxford) (2011) 0.84
The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis. BMC Med Res Methodol (2012) 0.84
Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int (2014) 0.84
74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther (2010) 0.83
A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol (2009) 0.83
Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept. Patient Prefer Adherence (2012) 0.82
Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) (2014) 0.82
Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol (2014) 0.82
Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biologics (2013) 0.81
Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. Rheumatol Int (2016) 0.80
Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. Clin Rheumatol (2013) 0.80
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. Ann Rheum Dis (2012) 0.80
Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Res Ther (2010) 0.80
Cellular targeting in autoimmunity. Curr Allergy Asthma Rep (2012) 0.80
Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract Res Clin Rheumatol (2010) 0.79
Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol (2013) 0.79
Translating co-stimulation blockade into clinical practice. Arthritis Res Ther (2008) 0.79
Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. Clin Rheumatol (2010) 0.79
Induction of remission in rheumatoid arthritis: criteria and opportunities. Rheumatol Int (2008) 0.79
Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study. Clin Rheumatol (2015) 0.78
Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians. Ther Adv Musculoskelet Dis (2014) 0.78
Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy. Clin Rheumatol (2009) 0.78
[Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration (FDA) announcement regarding cases of malignancy in anti-TNF-treated patients]. Z Rheumatol (2009) 0.78
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care Res (Hoboken) (2016) 0.77
Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs. Mod Rheumatol (2014) 0.77
Rationale of using different biological therapies in rheumatoid arthritis. Arthritis Res Ther (2010) 0.77
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis (2014) 0.77
[Recommedations for the use of abatacept in patients with rheumatoid arthritis]. Z Rheumatol (2008) 0.77
[Selective co-stimulation blockade. CTLA4-Ig (Abatacept)]. Z Rheumatol (2010) 0.76
Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. Lupus (2010) 0.76
[A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation]. Wien Med Wochenschr (2009) 0.76
The efficacy and safety of abatacept in rheumatoid arthritis. Ther Adv Musculoskelet Dis (2010) 0.75
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol (2012) 0.75
Relationship Between Lymph Node Volume and Pain Following Certolizumab Therapy for Rheumatoid Arthritis Flare: A Pilot Study. Clin Med Insights Arthritis Musculoskelet Disord (2016) 0.75
New pharmacological strategies in rheumatic diseases. J Med Life (2016) 0.75
Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison. Korean J Intern Med (2016) 0.75
How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA? Nat Clin Pract Rheumatol (2009) 0.75
Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature. Open Access Rheumatol (2013) 0.75
Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open (2017) 0.75
Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infect Dis (2016) 0.75
Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis. Open Access Rheumatol (2012) 0.75
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatol (2009) 0.75
Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open (2017) 0.75
Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate. CMAJ (2013) 0.75
New and emerging therapies for the treatment of rheumatoid arthritis. Open Access Rheumatol (2010) 0.75
The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice. Int J Rheumatol (2017) 0.75
Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain. Cost Eff Resour Alloc (2015) 0.75
Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med (2016) 0.75
Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis. Open Access Rheumatol (2009) 0.75
Blockade of co-stimulation in chronic inflammatory diseases. Wien Med Wochenschr (2014) 0.75
Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow. Curr Treatm Opt Rheumatol (2015) 0.75
[Recommendations for use of abatacept in patients with rheumatoid arthritis]. Z Rheumatol (2014) 0.75
Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs. Clin Rheumatol (2016) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum (1995) 15.00
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics (1999) 4.86
Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol (1993) 4.39
The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol (2005) 3.59
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum (2006) 2.54
The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol (2002) 1.38
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.37
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage (2008) 10.99
Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol (1993) 8.47
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2003) 7.95
OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage (2010) 7.52
Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature (1995) 6.62
Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A (2000) 6.59
Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. Nature (1990) 6.29
Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08
Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure (1998) 5.83
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
Regulation of flowering time by Arabidopsis photoreceptors. Science (1998) 5.11
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2004) 4.94
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum (2001) 4.57
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2000) 4.37
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage (2007) 4.34
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell (1996) 4.12
OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage (2004) 4.01
Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis (2004) 3.95
TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med (2001) 3.84
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Resistance studies with daptomycin. Antimicrob Agents Chemother (2001) 3.63
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Retinopathy and attenuated circadian entrainment in Crx-deficient mice. Nat Genet (1999) 3.42
Mechanism of NO-induced oxidation of myoglobin and hemoglobin. Biochemistry (1996) 3.36
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage (1996) 3.26
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol (1995) 3.10
[Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic (1990) 3.04
Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med (1998) 2.99
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
The Huntington's disease candidate region exhibits many different haplotypes. Nat Genet (1992) 2.84
Association between 5-HT2A gene promoter polymorphism and anorexia nervosa. Lancet (1997) 2.83
Antagonistic actions of Arabidopsis cryptochromes and phytochrome B in the regulation of floral induction. Development (1999) 2.76
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Role in cell permeability of an essential two-component system in Staphylococcus aureus. J Bacteriol (1999) 2.73
Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage (2005) 2.69
Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis (2006) 2.68
Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis (2004) 2.60
A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry (1996) 2.60
Constitutive expression of the cold-regulated Arabidopsis thaliana COR15a gene affects both chloroplast and protoplast freezing tolerance. Proc Natl Acad Sci U S A (1996) 2.58
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Rescue of cyclin D1 deficiency by knockin cyclin E. Cell (1999) 2.54
Measurement of genetic structure within populations using Moran's spatial autocorrelation statistics. Proc Natl Acad Sci U S A (1996) 2.48
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis (2003) 2.48
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis (2009) 2.44
Null RPGRIP1 alleles in patients with Leber congenital amaurosis. Am J Hum Genet (2001) 2.40
Synthesis of epothilones A and B in solid and solution phase. Nature (1997) 2.35
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis (2008) 2.33
The effect of multiple reexcisions on the risk of local recurrence after breast conserving surgery. Ann Surg Oncol (2007) 2.32
Management of osteoarthritis (OA) with an unsupervised home based exercise programme and/or patient administered assessment tools. A cluster randomised controlled trial with a 2x2 factorial design. Ann Rheum Dis (2004) 2.29
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 2.27
The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. Osteoarthritis Cartilage (2010) 2.24
Broad-spectrum mildew resistance in Arabidopsis thaliana mediated by RPW8. Science (2001) 2.23
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol (1999) 2.21
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Interaction between inclusions embedded in membranes. Biophys J (1996) 2.20
A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3). Proc Natl Acad Sci U S A (2000) 2.19
Molecular genetics of retinitis pigmentosa. Hum Mol Genet (1995) 2.18
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum (2011) 2.14
Nitric-oxide dioxygenase activity and function of flavohemoglobins. sensitivity to nitric oxide and carbon monoxide inhibition. J Biol Chem (2000) 2.13
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol (1999) 2.12
Rheumatic manifestations associated with human immunodeficiency virus infection. Arthritis Rheum (1989) 2.11
Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol (1997) 2.11
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Retinitis pigmentosa GTPase regulator (RPGRr)-interacting protein is stably associated with the photoreceptor ciliary axoneme and anchors RPGR to the connecting cilium. J Biol Chem (2000) 2.08
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Completely diverted tube ileostomy compared with loop ileostomy for protection of low colorectal anastomosis: a pilot study. Colorectal Dis (2014) 2.06
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis (2007) 2.01
Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication. J Virol (1997) 2.00
Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum (2001) 2.00
Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature (1997) 1.99
Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol (1994) 1.99
Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke (1999) 1.98
Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis (2011) 1.97
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum (2006) 1.96
Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase. Proc Natl Acad Sci U S A (1993) 1.95
One polypeptide with two aminoacyl-tRNA synthetase activities. Science (2000) 1.94